DJI46,558.47-0.26%
GDAXI23,447.29-0.60%
GSPC6,632.19-0.61%
HSI25,465.60-0.98%
IXIC22,105.36-0.93%
N22553,819.61-1.16%
AAPL250.12-2.21%
AMZN207.67-0.89%
CL98.71+3.11%
EURUSD1.1423-0.82%
GBPUSD1.3223-0.93%
GC5,061.70-1.25%
GOOG301.46-0.58%
JPM283.44+0.19%
META613.71-3.83%
MSFT395.55-1.58%
NVDA180.25-1.59%
TSLA391.20-0.96%
DJI46,558.47-0.26%
GDAXI23,447.29-0.60%
GSPC6,632.19-0.61%
HSI25,465.60-0.98%
IXIC22,105.36-0.93%
N22553,819.61-1.16%
AAPL250.12-2.21%
AMZN207.67-0.89%
CL98.71+3.11%
EURUSD1.1423-0.82%
GBPUSD1.3223-0.93%
GC5,061.70-1.25%
GOOG301.46-0.58%
JPM283.44+0.19%
META613.71-3.83%
MSFT395.55-1.58%
NVDA180.25-1.59%
TSLA391.20-0.96%
DJI46,558.47-0.26%
GDAXI23,447.29-0.60%
GSPC6,632.19-0.61%
HSI25,465.60-0.98%
IXIC22,105.36-0.93%
N22553,819.61-1.16%
AAPL250.12-2.21%
AMZN207.67-0.89%
CL98.71+3.11%
EURUSD1.1423-0.82%
GBPUSD1.3223-0.93%
GC5,061.70-1.25%
GOOG301.46-0.58%
JPM283.44+0.19%
META613.71-3.83%
MSFT395.55-1.58%
NVDA180.25-1.59%
TSLA391.20-0.96%
LIVE
SWE Dagens Industri SV

Efter kursslakten – storägaren tar över ordförandeklubban

På två år har 95 procent av Nanologicas börsvärde gått upp i rök.  Nu agerar största ägaren Flerie och Thomas Eldered – som tar över ordförandeklubban.  ”Vi behöver återvinna aktiemarknadens förtroende för att vi gör rätt saker”, säger han om det kurspressade innehavet.

Mar 10, 2026 &03071010202631; 14:07 UTC www.di.se Trending 2/5
Read original on www.di.se ↗
Negative for markets
Sentiment score: -65/100
High impact Medium-term (weeks)
WHAT THIS MEANS
Nanologica has lost 95% of its market value over two years, prompting major shareholder Flerie and Thomas Eldered to take over the chairman position. The new leadership aims to restore investor confidence in the struggling Swedish biotech company.
AI CONFIDENCE
0% Low
SENTIMENT GAUGE
NEWS POWER SCORE
AFFECTED ASSETS
NANOL.ST
NANOL.STStock
Expected to decline
Severe market capitalization erosion of 95% over two years; leadership change indicates distress but potential turnaround attempt
PRICE HISTORY
Loading chart...
SUGGESTED ACTION
Avoid or short Nanologica until concrete operational improvements are demonstrated. Monitor quarterly results closely for signs of stabilization; any positive catalysts could trigger short-covering rallies given the depressed valuation, but fundamental recovery remains uncertain.
KEY SIGNALS
Massive shareholder value destructionMajor shareholder intervention and leadership changeCredibility crisis requiring restorationPotential restructuring or strategic pivot ahead
SECTORS INVOLVED
BiotechnologyHealthcareSwedish Equities
Analysis generated on Mar 11, 2026 at 02:04 UTC
Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Dagens Industri. Always conduct your own research and consult a qualified financial advisor before making investment decisions.